Migdal Insurance & Financial Holdings Ltd. Purchases 1,950 Shares of Celgene Co. (CELG)

Migdal Insurance & Financial Holdings Ltd. boosted its position in Celgene Co. (NASDAQ:CELG) by 40.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,790 shares of the biopharmaceutical company’s stock after acquiring an additional 1,950 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Celgene were worth $895,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CELG. Todd Asset Management LLC bought a new position in Celgene in the first quarter valued at about $17,130,000. Groesbeck Investment Management Corp NJ boosted its holdings in Celgene by 3.5% in the first quarter. Groesbeck Investment Management Corp NJ now owns 4,455 shares of the biopharmaceutical company’s stock valued at $554,000 after acquiring an additional 150 shares during the last quarter. Marcus Capital LLC boosted its holdings in Celgene by 1.5% during the first quarter. Marcus Capital LLC now owns 11,550 shares of the biopharmaceutical company’s stock worth $1,437,000 after buying an additional 175 shares during the last quarter. Independent Advisor Alliance boosted its holdings in Celgene by 46.3% during the first quarter. Independent Advisor Alliance now owns 6,003 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 1,899 shares during the last quarter. Finally, Premier Asset Managment LLC boosted its holdings in Celgene by 5.0% during the first quarter. Premier Asset Managment LLC now owns 123,107 shares of the biopharmaceutical company’s stock worth $15,318,000 after buying an additional 5,840 shares during the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.

In related news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by company insiders.

CELG has been the topic of a number of recent analyst reports. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a report on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating on shares of Celgene in a report on Tuesday, August 22nd. BTIG Research restated a “neutral” rating on shares of Celgene in a report on Tuesday, September 5th. Cowen restated a “buy” rating and set a $150.00 target price on shares of Celgene in a report on Tuesday, September 12th. Finally, Bank of America restated a “buy” rating on shares of Celgene in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $139.57.

Celgene Co. (NASDAQ:CELG) opened at $106.09 on Friday. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $80,881.07, a PE ratio of 16.05, a PEG ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. Celgene’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts forecast that Celgene Co. will post 6.67 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/12/10/migdal-insurance-financial-holdings-ltd-purchases-1950-shares-of-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply